The clinical performance is complex and often involves multiple systemic burdens. Early identification and standardized clinical treatment are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can help align national and international experts and teams to provide accurate diagnosis and treatment programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many of the neural system diseases that have previously been difficult to treat have been significantly improved. Treatment needs to be closely monitored for effectiveness and adverse reactions, adjusted in a timely manner according to the changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of PML-related antibodies. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.